EANM Marie-Curie Award 2021 went to VIVIANE TSCHAN

Viviane Tschan, PhD student in the “Nuclide Chemistry” group at the Center for Radiopharmaceutical Sciences, received this year’s Marie Curie Award for a new concept of radioligand therapy of prostate cancer, presented at the ³⁴st Annual Conference of the European Association of Nuclear Medicine (EANM).

The preclinical research study demonstrated the favorable effect of a new PSMA radioligand ⁽¹⁷⁷Lu-Ibu-DAB-PSMA) compared to that of the clinically-applied ¹⁷⁷Lu-PSMA-617 for the treatment of prostate cancer. Ibu-DAB-PSMA was previously established in the “Nuclide Chemistry” group by Deberle & Benesova et al. (Theranostics 2020). It is characterized by a chemical modification with ibuprofen as an albumin-binding entity to enhance the blood circulation time and, as a result, increase the tumor uptake.